Substance Use Disorder Market Positioned for Accelerated Development Through 2034

The Substance Use Disorder Market Size is projected to grow at a robust CAGR during the study period (2020–2034). Over the forecast period from 2024 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Substance Use Disorder Market Landscape. By analyzing historical data, current Substance Use Disorder Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Substance Use Disorder Market is increasingly guided by biomarker-driven strategies. Substance Use Disorder (SUD) is a medical condition characterized by the uncontrollable use of substances—such as alcohol, drugs, or prescription medications—despite harmful consequences to one’s health, relationships, and daily life. It involves changes in brain function that lead to compulsive behavior, cravings, tolerance (needing more of the substance to achieve the same effect), and withdrawal symptoms when the substance is reduced or stopped. SUD can range from mild to severe and often requires a combination of medical, psychological, and behavioral interventions for effective treatment.

DelveInsight’s report, “Substance Use Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Substance Use Disorder Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Substance Use Disorder Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Substance Use Disorder Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Substance Use Disorder Market Forecast

Some of the key facts of the Substance Use Disorder Market Report

• The leading Substance Use Disorder Companies such as BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, and others.

• Promising Substance Use Disorder Therapies such as Quetiapine, Truvada, Brexpiprazole, Risperidone, XR-NTX, CAM2038 SC injection, TMP-301, and others.

• The Substance Use Disorder Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Substance Use Disorder Pipeline products will significantly revolutionize the Substance Use Disorder Market Dynamics.

Substance Use Disorder Overview

Substance Use Disorder (SUD) is a chronic brain condition where a person loses control over using substances like alcohol, drugs, or medications, continuing use even when it harms their health, relationships, or life. It often involves strong cravings, increased tolerance, and withdrawal symptoms, making it difficult to stop without proper treatment.

Get a Free sample for the Substance Use Disorder Market Report @ https://www.delveinsight.com/report-store/substance-use-disorder-market

Key Trends in the Substance Use Disorder Therapeutics Market

• Rising Prevalence of Substance Use Disorders

The market is driven by increasing cases of alcohol, opioid, and other drug dependencies worldwide, which is creating high demand for effective therapeutic options.

• Reduced Stigma and Increased Awareness

Greater recognition of SUD as a medical condition and reduced societal stigma are encouraging more individuals to seek treatment, expanding the patient base.

• Dominance of Medication-Assisted Treatment (MAT)

Traditional MAT approaches, including opioid agonists, antagonists, and alcohol/tobacco cessation drugs, continue to be the cornerstone of SUD management.

• Integration with Behavioral Therapies

Combining pharmacotherapy with counseling, cognitive-behavioral therapy, and holistic care improves treatment outcomes and lowers relapse rates.

• 5. Growth of Outpatient and Digital Care Models

Community-based programs, outpatient facilities, and telemedicine platforms are increasingly preferred due to convenience, accessibility, and scalability.

• Innovation in Therapeutics

Emerging treatments, such as long-acting injectables, extended-release formulations, and non-addictive agents, are reshaping the treatment landscape.

Substance Use Disorder Epidemiology Segmentation in the 7MM

The Substance Use Disorder Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Substance Use Disorder Diagnosed Prevalent Cases

• Substance Use Disorder Substance type-specific Cases

• Total Substance Use Disorder Treated Cases

Download the report to understand which factors are driving Substance Use Disorder Epidemiology trends @ Substance Use Disorder Epidemiology Forecast

Recent Development in the Substance Use Disorder Treatment Landscape

• In December 2025, Eli Lilly and Company announced a study to evaluate the safety and effectiveness of brenipatide versus placebo in participants with moderate-to-severe Alcohol Use Disorder (AUD), with a study duration of approximately 56 weeks.

Substance Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Substance Use Disorder drugs recently launched in the Substance Use Disorder market or expected to get launched during the study period. The analysis covers Substance Use Disorder Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Substance Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Substance Use Disorder Companies and Therapies

• Creighton University: Quetiapine/Risperidone

• Seattle Institute for Biomedical and Clinical Research: Quetiapine

• Tuscaloosa Research & Education Advancement Corporation: Risperidone/Divalproex sodium ER

• Tempero Bio Inc.: TMP-301

• Imbrium Therapeutics: Sunobinop

To know more about Substance Use Disorder Companies working in the treatment market, visit @ Substance Use Disorder Clinical Trials and Therapeutic Assessment

Substance Use Disorder Market Drivers

• Rising Prevalence of Substance Use Disorders

The global increase in opioid, alcohol, and illicit drug consumption is driving demand for effective therapeutics. Socioeconomic and psychological stressors further contribute to the growing patient population requiring treatment.

• Advancements in Treatment Options

Development of novel pharmacotherapies, long-acting formulations, and combination therapies is enhancing treatment outcomes, improving patient adherence, and reducing relapse rates in substance use disorder management.

• Growing Awareness and Acceptance of Addiction Treatment

Increasing understanding of mental health and addiction issues is encouraging more individuals to seek professional treatment, expanding the addressable market for therapeutics.

• Supportive Government Initiatives and Regulatory Frameworks

Policies promoting access to addiction treatment, research funding, and inclusion of SUD management in public healthcare programs are facilitating market growth.

Substance Use Disorder Market Barriers

• Societal Stigma Limiting Treatment Adoption

Stigma associated with substance use disorders discourages patients from seeking care and can influence healthcare providers, limiting proactive diagnosis and intervention.

• Stringent Regulatory and Approval Challenges

The SUD therapeutics market faces complex regulatory hurdles, including lengthy clinical trials and varying approval processes across regions, which can delay market entry for novel therapies.

• High Treatment Costs and Limited Reimbursement

Many patients are unable to afford long-term treatments due to high costs and restricted reimbursement options, especially in low- and middle-income regions, limiting therapy accessibility.

• Lack of Awareness and Education among Stakeholders

Limited knowledge among patients and healthcare professionals about emerging therapies results in reliance on traditional treatments, slowing the adoption of innovative approaches.

• Treatment Adherence and Relapse Challenges

High relapse rates, side effects, and complex dosing schedules hinder long-term treatment success. Fragmented healthcare infrastructure and insufficient integration of behavioral and pharmacological therapies add to these challenges.

Scope of the Substance Use Disorder Market Report

• Coverage- 7MM

• Study Period-2020-2034

• Substance Use Disorder Companies- BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, and others.

• Substance Use Disorder Therapies- Quetiapine, Truvada, Brexpiprazole, Risperidone, XR-NTX, CAM2038 SC injection, TMP-301, and others.

• Substance Use Disorder Therapeutic Assessment: Substance Use Disorder current marketed and Substance Use Disorder emerging therapies

• Substance Use Disorder Market Dynamics: Substance Use Disorder market drivers and Substance Use Disorder market barriers

• Substance Use Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Substance Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Substance Use Disorder Market Access and Reimbursement

Discover more about therapies set to grab major Substance Use Disorder Market Share @ Substance Use Disorder Treatment Market

Table of Contents

1. Key Insights

2. Substance Use Disorder Market Report Introduction

3. Substance Use Disorder Market Overview at a Glance

4. Substance Use Disorder Executive Summary

5. Key Events

6. Substance Use Disorder Market Disease Background and Overview

7. Substance Use Disorder Methodology

8. Substance Use Disorder Population

9. Substance Use Disorder Patient Journey

10. Substance Use Disorder Marketed Drugs

11. Substance Use Disorder Emerging Drugs

12. Substance Use Disorder – 7MM Market Analysis

13. Substance Use Disorder KOL Views

14. Substance Use Disorder Unmet Needs

15. Substance Use Disorder SWOT Analysis

16. Substance Use Disorder Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.